Your session is about to expire
← Back to Search
Histamine H2 Receptor Antagonist
Famotidine vs Placebo for the Treatment of Non-Hospitalized Adults With COVID-19
Phase 2
Waitlist Available
Led By Tobias Janowitz, MD, PhD
Research Sponsored by Northwell Health
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 7, 14, and 28.
Summary
The overall objective of this study is to evaluate the clinical efficacy of oral famotidine in symptomatic non-hospitalized patients with confirmed COVID-19. This study is expected to enroll up to 84 patients with mild to moderate symptoms divided into each of the two study arms. Clinical outcomes of the two treatment arms will be compared. This study will be conducted virtually/remotely.
Eligible Conditions
- Coronavirus
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ day 7, 14, and 28.
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 7, 14, and 28.
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Secondary study objectives
Assessment of Serious Adverse Events
Change in CRP
Change in ferritin
+8 moreTrial Design
2Treatment groups
Active Control
Placebo Group
Group I: FamotidineActive Control1 Intervention
Participants in this study arm will receive standard of care and prescribed famotidine at 80mg TID for a maximum of 14 days, or until hospital admission.
Group II: PlaceboPlacebo Group1 Intervention
Participants in this study arm will receive standard of care and placebo for a maximum of 14 days.
Find a Location
Who is running the clinical trial?
Northwell HealthLead Sponsor
474 Previous Clinical Trials
469,078 Total Patients Enrolled
Cold Spring Harbor LaboratoryOTHER
10 Previous Clinical Trials
20,086 Total Patients Enrolled
Tobias Janowitz, MD, PhDPrincipal InvestigatorCold Spring Harbor Laboratory